(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Don't plan to cook on Thanksgiving? Here are the restaurants and fast food places that are scheduled to be open - 2Must-See Attractions in Australia
- 3Parents who delay baby's first vaccines also likely to skip measles shots
- 4Should you get an RSV vaccine this fall? What to know and where to get a shot
- 510 Setting up camp Shelters That Offer Both Excellence and Isolation
- Fossil analysis changes what paleontologists know about how long T. rex took to grow full size
- Understanding Preschool Projects: An Extensive Aide
- Find the Lively Food Markets of South America
- Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- A Manual for Well known Western television Series
- Book excerpt: "Enough" by Dr. Ania Jastreboff and Oprah Winfrey
- Share your number one city visit transport that leaves a mark on the world wake up!
- 4 injured in shooting at North Carolina tree lighting ceremony
- She just became the first wheelchair user to travel to space
